Achillion Pharmaceuticals Inc (ACHN)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

300 GEORGE STREET NEW HAVEN, CT 06511

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases. It focuses on the development of antivirals for the treatment of HIV infection and chronic hepatitis C; and antibacterials for the treatment of serious hospital-based bacterial infections. The company's lead drug candidate is elvucitabine, an antiviral in phase II clinical trials for the treatment of HIV infection. It also develops ACH-702, a preclinical candidate for the treatment of serious hospital-based bacterial infection; and NS4A Antagonists, a preclinical-stage program for chronic hepatitis C. The company has research collaboration with Gilead Sciences, Inc. to develop and commercialize compounds for the treatment of chronic hepatitis C.

Data as of 2019-12-02 11:29:43 -0500
Market Cap869.971 Million Shares Outstanding140.092 Million Avg 30-day Volume
P/E Ratio Dividend Yield EPS-0.537
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE Enterprise Value
Total Cash Current Debt Gross Profit
BETA 52-week High/Low6.46 / 1.29 Next Earnings Date Price to Cash FLow (P/CF)
Data provided by IEX Cloud
View SEC Filings from ACHN instead.
Q4 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) No data
Funds Holding: 2 0 (0.0%) No data
13F shares: 4 Thousand 0 No data
% Ownership No data
New Positions: 1 No data
Increased Positions No data
Closed Positions No data
Reduced Positions No data
Total Calls No data
Total Puts No data
PUT/CALL Ratio No data No data
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ACHN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ACHN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

FISHERMAN JASON S

0 2020-01-28 0

VITULLO NICOLE

  • Director
0 2020-01-28 0

TRUITT JOSEPH CHIEF EXECUTIVE OFFICER

0 2020-01-28 0

KISHBAUCH MICHAEL D

0 2020-01-28 0

SCHEER DAVID

0 2020-01-28 0

VAN NOSTRAND ROBERT L

0 2020-01-28 0

GRAVES KURT

0 2020-01-28 0

VERWIEL FRANK

0 2020-01-28 0

MANNING MARTHA E GENERAL COUNSEL

0 2020-01-28 0

GIBNEY ANTHONY S EVP, CHIEF BUSINESS OFFICER

0 2020-01-28 0

ZELENKOFSKE STEVEN EVP, CHIEF MEDICAL OFFICER

0 2020-01-28 0

FIRUTA PAUL E EVP, CHIEF COMMERCIAL OFFICER

0 2020-01-28 0

DI DONATO BRIAN SVP, CHIEF FINANCIAL OFFICER

0 2020-01-28 0

G1 EXECUTION SERVICES, LLC

SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC

SUSQUEHANNA SECURITIES, LLC

  • 10% Owner
0 2020-01-28 0

LANTZ KERI SEE REMARKS

  • Officer
0 2019-01-23 0

DESHPANDE MILIND CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2018-02-09 0

FENTON MARY KAY CHIEF FINANCIAL OFFICER

  • Officer
0 2018-02-09 0

FRASHIER GARY E

  • Director
0 2018-02-09 0

JOHNSON & JOHNSON

JOHNSON & JOHNSON INNOVATION - JJDC, INC.

  • 10% Owner
No longer subject to file 2017-11-20 0

APELIAN DAVID CHIEF MEDICAL OFFICER

  • Officer
0 2017-01-17 0

BARRISH JOEL C CHIEF SCIENTIFIC OFFICER

  • Officer
0 2017-01-17 0

SHAH GAUTAM EVP AND CHIEF COMPLIANCE OFC.

  • Officer
0 2014-12-02 0

LIOTTA DENNIS

  • Director
0 2014-12-02 0

RA CAPITAL MANAGEMENT, LLC

KOLCHINSKY PETER

RA CAPITAL HEALTHCARE FUND LP

  • FORMER 10% OWNER, SEE FN(5)(6)FORMER 10% OWNER, SEE FN(5)(6)FORMER 10% OWNER, SEE FN(5)(6)
No longer subject to file 2014-09-29 0

RA CAPITAL MANAGEMENT, LLC

  • 10% Owner
  • SEE FOOTNOTES (1)(5)
22,486,007 2014-06-20 0

QVT ASSOCIATES GP LLC

  • 10% Owner
No longer subject to file 2014-06-16 0

QVT ASSOCIATES GP LLC

QVT FUND V LP

  • 10% Owner
11,712,953 2013-09-30 0

DOMAIN PARTNERS VIII, L.P.

  • 10% Owner
5,772,968 2013-01-18 0

BLAIR JAMES C

  • 10% Owner
6,017,025 2013-01-18 0

HALAK BRIAN K

  • 10% Owner
6,017,025 2013-01-18 0

SCHOEMAKER KATHLEEN K

  • 10% Owner
6,017,025 2013-01-18 0

TREU JESSE I

  • 10% Owner
6,017,025 2013-01-18 0

DOVEY BRIAN H

  • 10% Owner
6,017,025 2013-01-18 0

WRIGHT DAVID P

  • Director
0 2012-12-18 0

SIMON NICHOLAS

  • Director
73,593 2012-06-04 0

CLARUS LIFESCIENCES II, L.P.

CLARUS VENTURES II GP, L.P.

CLARUS VENTURES II, LLC

LIPTAK ROBERT

HENNER DENNIS

GALAKATOS NICHOLAS

WHEELER KURT

STEINMETZ MICHAEL

  • 10% Owner
No longer subject to file 2012-06-04 0

CLARUS LIFESCIENCES II, L.P.

CLARUS VENTURES II GP, L.P.

CLARUS VENTURES II, LLC

LIPTAK ROBERT

SIMON NICHOLAS

HENNER DENNIS

GALAKATOS NICHOLAS

WHEELER KURT

STEINMETZ MICHAEL

  • Director
  • 10% Owner
10,942,471 2012-05-31 0

OLEK ELIZABETH A SVP AND CMO

  • Officer
2,000 2012-01-10 0

QUAKER BIOVENTURES II LP

  • 10% Owner
No longer subject to file 2011-03-07 0

KAMDAR KIM P.

  • 10% Owner
25,000 2011-01-01 0

DOMAIN ASSOCIATES

  • 10% Owner
25,000 2010-10-06 0

CLARUS LIFESCIENCES II, L.P.

CLARUS VENTURES II GP, L.P.

CLARUS VENTURES II, LLC

LIPTAK ROBERT

SIMON NICHOLAS

HENNER DENNIS

GALAKATOS NICHOLAS

LEIDEN JEFFREY

WHEELER KURT

STEINMETZ MICHAEL

  • Director
  • 10% Owner
9,262,079 2010-08-20 0

DP VIII ASSOCIATES, L.P.

  • 10% Owner
59,161 2010-08-20 0

INVESTOR AB

INVESTOR GROWTH CAPITAL LTD

  • 10% Owner
No longer subject to file 2009-12-31 0

GREY MICHAEL G

  • Director
0 2009-12-18 0

MOORIN JAY

SCHREIBER ALAIN

PROQUEST ASSOCIATES IV LLC

PROQUEST INVESTMENTS IV, L.P.

  • 10% Owner
No longer subject to file 2009-12-16 0

INVESTOR AB

  • 10% Owner
2,548,360 2008-12-04 0

INVESTOR GROWTH CAPITAL LTD

  • 10% Owner
1,783,862 2008-12-04 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments